Journal
CLINICAL INFECTIOUS DISEASES
Volume 54, Issue -, Pages S23-S34Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/cir866
Keywords
-
Categories
Funding
- Henry Schueler 419 Foundation
- Gilead
- Pfizer
- Schering Plough
- Aventis
- Merck Sharp Dohme (MSD)
- Enzon
- Schering
- Wyeth
- Novartis
- Astellas
- Merck
- Fujisawa Pharmaceutical
- Enzon Pharmaceuticals
Ask authors/readers for more resources
Mucormycosis is an emerging angioinvasive infection caused by the ubiquitous filamentous fungi of the Mucorales order of the class of Zygomycetes. Mucormycosis has emerged as the third most common invasive mycosis in order of importance after candidiasis and aspergillosis in patients with hematological and allogeneic stem cell transplantation. Mucormycosis also remains a threat in patients with diabetes mellitus in the Western world. Furthermore, this disease is increasingly recognized in recently developed countries, such as India, mainly in patients with uncontrolled diabetes or trauma. Epidemiological data on this type of mycosis are scant. Therefore, our ability to determine the burden of disease is limited. Based on anatomic localization, mucormycosis can be classified as one of 6 forms: (1) rhinocerebral, (2) pulmonary, (3) cutaneous, (4) gastrointestinal, (5) disseminated, and (6) uncommon presentations. The underlying conditions can influence clinical presentation and outcome. This review describes the emerging epidemiology and the clinical manifestations of mucormycosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available